Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 33 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. FDA U.S. Food and Drug Administration 2017:21 de septiembre. [Ref.ID 102061]
2. Cita con resumen
Anónimo. EMA advisory committee conditionally approves obeticholic acid. DIA Daily 2016:4. [Ref.ID 100812]
3.Tiene citas relacionadas
Pratt DS. Primary biliary cholangitis - A new name and a new treatment. N Engl J Med 2016;375:688-95. [Ref.ID 100714]
4.Tiene citas relacionadas Cita con resumen
Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JPH, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall H-U, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D, for the POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-43. [Ref.ID 100712]
5. Cita con resumen
Anónimo. FDA Advisory Panel unanimously recommends approval of new liver drug. FDA U.S. Food and Drug Administration 2016:2. [Ref.ID 100108]
6. Cita con resumen
Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007;357:1524-9. [Ref.ID 81215]
7. Cita con resumen
Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, O'Grady JG, Castaing D, Klempnauer J, Jamieson N, Neuhaus P, Lerut J, de Ville de Goyet J, Pollard S, Salizzoni M, Rogiers X, Muhlbacher F, García Valdecasas JC, Broelsch C, Jaeck D, Berenguer J, Moreno González E, Adam R, on behalf of the European Liver Transplant Association. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006;367:225-32. [Ref.ID 75998]
8.
Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-73. [Ref.ID 74839]
9. Cita con resumen
Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002;359:1309-10. [Ref.ID 61399]
10.
Anónimo. Acide ursodésoxycholique. Cirrhose biliaire primitive: un espoir déçu. Prescrire 2001;21:822-5. [Ref.ID 60638]
11.Tiene citas relacionadas
Burroughs AK, Goulis J, Leandro G. Ursodeoxycholic acid for primary biliary cirrhosis. Authors' reply. Lancet 2000;355:658. [Ref.ID 49462]
12.Tiene citas relacionadas
Lindor KD, Poupon R, Poupon R, Heathcote EJ, Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000;355:657-8. [Ref.ID 49461]
13. Cita con resumen
Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-60. [Ref.ID 46956]
14. Cita con resumen
Anónimo. Ursodeoxycholic acid for primary biliary cirrhosis. Drug Ther Bull 1999;37:30-2. [Ref.ID 43959]
15. Cita con resumen
Zylicz Z, Krajnik M. Codeine for pruritus in primary billiary cirrhosis. Lancet 1999;353:813. [Ref.ID 43490]
16.
LaRusso N. Search for medical treatment for primary biliary cirrhosis. Lancet 1997;350:1046. [Ref.ID 35459]
17.
Neuberger J. Primary biliary cirrhosis. Lancet 1997;350:875-9. [Ref.ID 35395]
18.
Lindor KD. Primary biliary cirrhosis: questions and promises. Ann Intern Med 1997;126:733-5. [Ref.ID 32458]
19.
Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997;126:682-8. [Ref.ID 32452]
20. Cita con resumen
Anónimo. Methotrexate and liver disease. Lancet 1997;349:1300. [Ref.ID 32311]
Seleccionar todas
 
 1 a 20 de 33 siguiente >>